Table 3 RAL plasmatic concentrations [RAL]plasma and [RAL-glu]plasma/[RAL]plasma ratio depending on UGT1A1 allelic status.

From: Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients

 

[RAL]plasma (ng/ml)*

p-value

MR

p-value

UGT1A1*1/*1

n = 42

88.5 (41.0–236)

0.03**

0.03***

5.8 (3–10)

0.006**

0.005***

UGT1A1*28 carrier

n = 48

168 (85.8–318)

2.9 (1.6–5.3)

UGT1A1*36 carrier

n = 6

92.5 (36.4–316)

 

3.2 (1.7–5.9)

 
  1. *Concentrations are expressed as median with interquartile range (IQR).
  2. **Kruskal-Wallis test.
  3. ***Steel–Dwass post-hoc test.
  4. MR:metabolic ratio ([RAL-glu]plasma/[RAL]plasma).
Back to article page